Tesamorelin

Lipodystrophy models refer to abnormal or pathological fat distribution and metabolism. The primary feature is the irregular distribution of fat into depots, leading to loss of fat (lipoatrophy) from specific areas, and accumulation of excess fat (lipohypertrophy) in other regions. This abnormal fat distribution is often associated with serious negative metabolic changes, including insulin resistance and elevated cholesterol and triglyceride levels. Two phase III studies were conducted with 806 test subjects over 26 weeks, followed by another 26-week extension.

Researchers posit that serious immunodeficiencies may induce non-alcoholic fatty liver disease (NAFLD), reported in nearly 40% of HIV-positive test models. In this study, 61 test subjects with HIV and a high hepatic fat fraction (HFF) were selected as test models and influenced with Tesamorelin or a placebo for 12 months. After 12 months, it was reported that 35% of subjects presented with Tesamorelin exhibited an apparent reduction in HFF rate by less than 5%, vs. only 4% of subjects receiving placebo. There was no reported alteration in glucose levels.

In this clinical study, immunodeficient models with mild cognitive impairment were observed. The main intent was to determine Tesamorelin's potential effect on neurological functioning. 100 subjects aged more than 40 years participated in this trial and underwent Tesamorelin presentation daily for 6 months, followed by 6 months without Tesamorelin, then re-introduction once a day for another 6 months. The primary outcome was reported in changes in neurocognitive performance measured by the Global Deficit Score (GDS) after 6 and 12 months. This study is underway, and the final results have not been published.

The main aim of this study was to determine any potential Tesamorelin might exhibit in altering insulin sensitivity. In this clinical trial setting, 53 test subjects with Type II diabetes were observed in a 12-week randomized trial. The subjects were divided into three groups, each receiving a lower or higher concentration of Tesamorelin or a placebo. Following the study period of 12 weeks, the concentration of fasting glucose, glycosylated hemoglobin, and diabetes control was measured. There was no reported significant reduction in either of these parameters, and the results of all three groups appeared to be indifferent.

In a research investigation, the possible impacts of Tesamorelin on the structural quality of muscle tissues were evaluated using computed tomography (CT) scans. The findings tentatively suggested a potential association between Tesamorelin and improvements in the density and overall volume of muscle tissues. Specific muscle groups, particularly the rectus abdominis, psoas major, and paraspinal muscles, exhibited more noticeable variations.

Visceral obesity involves the accumulation of excess fat around and within internal organs, a condition often observed in models of lipodystrophy. This form of excessive fat accumulation is potentially linked to several metabolic issues, including insulin resistance, the development of atherosclerosis, elevated LDL cholesterol levels, and hyperuricemia. Research into Tesamorelin has suggested it may lead to a reduction of up to 25% in visceral fat among lipodystrophy models.